Home › Funds › Palo Alto Investors LP › IOVA

Palo Alto Investors LP position in IOVA

IOVANCE BIOTHERAPEUTICS INC · Health Care

Palo Alto Investors LP reported holding 3,471,456 shares of IOVA (IOVANCE BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$51.4M, representing 7.65% of its reported portfolio and ranking #2 among its reported holdings. Palo Alto Investors LP has disclosed IOVA holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)3.47M sh
Reported value held$51.45M
Portfolio Weight7.65%
First reportedQ4 2023
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Palo Alto Investors LP's IOVA position evolved

Palo Alto Investors LP first disclosed a stake in IOVA in Q4 2023 at 2,106,792 shares (US$17.1M). The position peaked in Q3 2026 at 3,471,456 shares, worth US$51.4M. Across 12 filings, Palo Alto Investors LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 3,471,456 shares valued at US$51.4M — a reduction of -1,824,753 shares quarter over quarter.. Notable position changes include a 44% increase in Q3 2024 (shares fell 21% over the following quarter), a 122% increase in Q3 2025 (shares rose 26% over the following quarter), a 34% trim in Q3 2026 (shares fell 49% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 2.11M $17.13M New
Q1 2024 2.11M $31.31M Hold
Q2 2024 2.12M $16.97M Hold
Q3 2024 3.04M $28.56M Add
Q4 2024 3.04M $22.51M Hold
Q1 2025 3.21M $10.69M Add
Q2 2025 3.43M $5.90M Add
Q3 2025 7.62M $16.53M Add
Q4 2025 7.12M $19.43M Reduce
Q1 2026 6.35M $22.29M Reduce
Q2 2026 5.30M $22.03M Reduce
Q3 2026 3.47M $51.45M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IOVA and 13F data

IOVA (IOVANCE BIOTHERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in IOVA — the largest reported positions include MHR FUND MANAGEMENT LLC (US$429.3M), MPM BioImpact LLC (US$42.0M), Rhenman & Partners Asset Management AB (US$37.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IOVA

All IOVA fund holders →

FAQ

How long has Palo Alto Investors LP held IOVA?

Palo Alto Investors LP has disclosed IOVA holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Palo Alto Investors LP's current position in IOVA?

As of Q3 2026, Palo Alto Investors LP holds 3.47M shares of IOVA (IOVANCE BIOTHERAPEUTICS INC), valued at $51.45M, representing 7.65% of its reported portfolio and ranking #2.

Has Palo Alto Investors LP been buying or selling IOVA?

In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in IOVA. The position peaked in Q3 2026 at 3.47M shares.

Which other funds hold IOVA?

Other major institutional holders of IOVA include MHR FUND MANAGEMENT LLC, MPM BioImpact LLC, Rhenman & Partners Asset Management AB, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.